Roche’s Polivy Set For Blockbuster Sales After Frontline Lymphoma Success
First Progress In Frontline DLBCL In 20 Years
Roche has not disclosed the full data yet, but is confident that Polivy can surpass CAR-Ts and other competitors to be the new standard of care.
You may also be interested in...
The firm’s antibody-drug conjugate plus Rituxan and R-CHP chemoimmunotherapy has won a US thumbs up for first-line diffuse large B-cell lymphoma but lingering concerns about magnitude of benefit could lead to limited uptake.
Pharma chief Bill Anderson was optimistic about growth prospects, and downplayed Roche’s reliance on two near-term readouts at an investor day in London.
Roche presents further analysis on Tecentriq’s potential first-in-class adjuvant use, which could add up to $3bn a year to revenues.